NASDAQ:AUPH (Aurinia Pharmaceuticals Inc.)
About AUPH
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Latest News
Coronavirus
3 TSX Stocks Bay Street Expects Could Double or Triple in 1 Year!
Investing
Value Investors: 1 Pharma Growth Stock With Huge Potential
Stocks for Beginners
3 Top Canadian Pharma Stocks for Ambitious Investors
Top TSX Stocks
3 BioPharm Stocks Yielding 100% Yearly Returns
Investing
3 Stocks That Could Benefit From Canada’s Population Boom
Investing
Which Canadian Healthcare Stocks Could Make You Rich?
Investing
This Unloved Drug Stock Could Have Massive Upside
Investing
3 High-Performing Stocks to Buy on the Dip
Investing
TSX Reaches 16,000: These Are 5 of the Highest-Performing Stocks This Year
Dividend Stocks
3 Stocks That Have Soared Higher Than Shopify Inc. This Year!
❮2